Merck Sharp & Dohme Corporation v. Albrecht
Certiorari Denied
Petition for certiorari denied on June 16, 2025.
Docket No.24-977
Issue
Whether, if a pharmaceutical manufacturer fully informs the Food & Drug Administration of all material information bearing on a drug’s potential risk and seeks approval to warn of that risk on the label, but the FDA formally denies the request without mandating any alternative warning, the manufacturer may nonetheless be held liable under state law for failure to warn of that risk.
Jan 16, 2025Application (24A720) to extend the time to file a petition for a writ of certiorari from February 17, 2025 to March 19, 2025, submitted to Justice Alito.
Jan 24, 2025Application (24A720) granted by Justice Alito extending the time to file until March 19, 2025.
Mar 10, 2025Petition for a writ of certiorari filed. (Response due April 11, 2025)Apr 2, 2025Motion to extend the time to file a response from April 11, 2025 to May 12, 2025, submitted to The Clerk.Apr 3, 2025Motion to extend the time to file a response is granted and the time is extended to and including May 12, 2025.
Apr 11, 2025Brief amicus curiae of Pharmaceutical Research and Manufacturers of America filed.Apr 11, 2025Brief amicus curiae of Washington Legal Foundation filed.Apr 11, 2025Brief amicus curiae of Product Liability Advisory Council, Inc. filed.May 12, 2025Brief of respondents Doris Albrecht, et al. in opposition filed.May 23, 2025Reply of petitioner Merck Sharp & Dohme Corporation filed. (Distributed)May 27, 2025DISTRIBUTED for Conference of 6/12/2025.
Jun 16, 2025Petition DENIED.
Recommended Citation: Merck Sharp & Dohme Corporation v. Albrecht, SCOTUSblog, https://www.scotusblog.com/cases/merck-sharp-dohme-corporation-v-albrecht/